Immune checkpoint inhibitors are cancer treatments that have significantly improved the survival of patients with metastatic melanoma, lung and kidney cancer. However, checkpoint inhibitors are associated with side effects such as rashes, diarrhea, and in some cases more severe side effects such as colitis. If recognized early, side effects are mostly reversible and knowledge of the timing of onset of the side effect can be helpful for prompt clinical management by oncologists. If not recognized early and managed promptly, side effects can be life threatening, lead to unscheduled breaks or discontinuation of the checkpoint inhibitor treatment, and ultimately lead to cancer progression and caner-related mortality. The goal of this proposal is to establish the feasibility of an evidence-based, web-delivered oncology program, “OncoLink” to improve the management of immune checkpoint inhibitor side effects. If found effective, OncoLink has the potential to improve the care of patients receiving immune checkpoint inhibitors and may improve clinical outcomes such as disease progression and survival.
|Effective start/end date||7/1/18 → 7/31/21|
- American Cancer Society (Agreement 8/10/18)
- Bristol-Myers Squibb Company (Agreement 8/10/18)
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.